📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-03 11:36
12 analysed today
12
Today
133,654
All-time analysed
40,136
Positive
6,284
Negative
79,412
Neutral
7,754
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
25 announcements match the current filters (relevance ≥ 5).
Bajaj Healthcare sets Sep 14, 2026 as record date for ₹1.50/share (30%) final dividend
Bajaj Healthcare Limited has fixed Monday, September 14, 2026, as the record date for determining shareholder entitlement to a final dividend. The proposed dividend is 30%, or ₹1.50 per equity share, for FY 2025-26. Payment remains subject to approval by shareholders at the upcoming Annual General Meeting.
Confidence: HIGH
What changedThe company established the formal record date to determine eligibility for the FY26 final dividend of ₹1.50 per share.
Why it mattersProvides dividend clarity for shareholders; representing a modest dividend yield of approximately 0.45% on the current market price of ₹334.
Dividend per share: ₹1.50Dividend percentage: 30%Record Date: 14-Sep-2026Dividend yield at ₹334 price: ~0.45%
📅 Short termThe stock will trade ex-dividend ahead of September 14, 2026, followed by payout post-AGM approval.
📈 Long termLimited; routine corporate action reflecting ongoing operational cash flows and standard shareholder payouts.
Key Highlights
Fixed September 14, 2026, as the record date for final dividend eligibility.
Proposed final dividend of ₹1.50 per equity share (30% on face value).
Applicable for the financial year 2025-26, subject to shareholder approval at the AGM.
👀 What to Watch
Investors seeking dividend entitlement must hold shares prior to the ex-dividend date associated with the September 14, 2026 record date.
Bajaj Healthcare receives DCGI approval as first to launch Cenobamate in India
Bajaj Healthcare has received final approval from the Drug Controller General of India (DCGI) to manufacture and market Cenobamate API and Tablets. The company is the first to launch this next-generation antiseizure medication in India, targeting partial-onset seizures in adults. The approval covers six tablet strengths ranging from 12.5 mg to 200 mg. This move strengthens the company's Central Nervous System (CNS) portfolio, which is a key part of its strategy to move into higher-value pharmaceutical products.
Confidence: HIGH
What changedBajaj Healthcare has moved from a regulatory recommendation to final DCGI approval for manufacturing and marketing Cenobamate API and tablets.
Why it mattersBeing the first to launch a specific antiseizure medication in India provides a competitive edge in the CNS therapeutic area. This aligns with the company's goal of improving profitability (TTM OPM 17.4%) by focusing on complex and high-value products.
Tablet strengths approved: 6TTM Revenue: ₹420 CrMarket Cap: ₹1043 CrApproval Date: August 12, 2026
📅 Short termThe stock may see positive sentiment as the first-mover status in a specialized drug category is a notable milestone for a mid-cap pharma player.
📈 Long termIf successfully commercialized, this product could structurally improve the company's product mix and margins within the CNS segment over the next 2-3 years.
⚠ Risk flags
- Market adoption rate for a new epilepsy therapy
- Potential competition from larger generic manufacturers in the future
- Execution risk in scaling the CNS franchise
Key Highlights
First company to launch Cenobamate in the Indian market
Approval granted for 6 different tablet strengths: 12.5mg, 25mg, 50mg, 100mg, 150mg, and 200mg
Follows the Subject Expert Committee (SEC) recommendation received on June 26, 2026
Targets the CNS segment, specifically for adults with inadequately controlled epilepsy
Integrated approach involving both API and formulation manufacturing
👀 What to Watch
Investors should monitor the commercial launch timeline and the subsequent impact on the CNS segment's revenue contribution in the FY27 quarterly results. The first-mover advantage is significant, but the speed of market penetration and potential entry of competitors will determine long-term margin benefits.
IND A Rating Upgrade: Bajaj Healthcare Debt Facilities Reduced to ₹282 Cr
India Ratings (Ind-Ra) has upgraded Bajaj Healthcare's long-term rating to 'IND A' from 'IND A-' and short-term rating to 'IND A1' from 'IND A2+'. The upgrade is driven by improved credit metrics, with net leverage falling to 2.1x in FY26 from 4.7x in FY24, and interest coverage rising to 4.7x. Revenue grew to ₹611 Cr in FY26 with EBITDA margins expanding to 17.2%. The company is pivoting towards regulated markets and CDMO services, which now account for 10% of total revenue.
Confidence: HIGH
What changedIndia Ratings upgraded the company's credit profile by one notch and reduced the total quantum of rated debt facilities.
Why it mattersA higher credit rating typically leads to lower borrowing costs and reflects the company's successful deleveraging and shift toward higher-margin CDMO and regulated market segments.
Upgraded Long-term Rating: IND ATotal Bank Facilities: ₹282 CrFY26 Revenue: ₹611 CrNet Leverage (FY26): 2.1xPlanned Capex: ₹50 CrCapex vs Net Worth: ~9.4%
📅 Short termThe upgrade provides a positive sentiment boost and confirms the company's improving financial health following a recovery from FY24 losses.
📈 Long termThe strategic shift to CDMO (10% of revenue) and regulated markets, supported by a stronger balance sheet, positions the company for sustainable margin expansion.
⚠ Risk flags
- Elongated working capital cycle (200 days)
- Regulatory compliance risks at manufacturing plants
- Currency volatility (30% revenue in foreign currency)
Key Highlights
Long-term credit rating upgraded to 'IND A' with a Stable outlook
Total rated bank loan facilities reduced to ₹282 Cr from ₹332.6 Cr
Net leverage improved to 2.1x in FY26, down from 2.9x in FY25
Planned ₹50 Cr capex for a new R&D center and a 250 kg/annum peptide API facility
EBITDA margins improved to 17.2% in FY26, with management targeting 18-19% over the medium term
👀 What to Watch
Watch for the commissioning of the peptide API facility in Q4FY27 and the company's ability to further reduce its 200-day working capital cycle.
Bajaj Healthcare targets ₹1,000 Cr revenue in 3 years; Q1 FY27 PAT up 14% to ₹13.9 Cr
Bajaj Healthcare reported a steady Q1 FY27 with revenue growing 11.3% YoY to ₹165.6 Cr and PAT rising 14.1% to ₹13.9 Cr. The company is undergoing a structural shift toward high-value segments, including Peptides and Oncology, with a new 250 kg/annum peptide facility slated for Q4 FY27. Management has provided a clear growth guidance of 10-15% for FY27 and a long-term revenue target of ₹900-1,000 Cr within 2-3 years. Notably, the balance sheet has deleveraged significantly, with the Debt-to-Equity ratio falling to 0.45 from 1.19 in FY24.
Confidence: HIGH
What changedThe company has transitioned from a routine API manufacturer to a high-value specialty player with a focus on Peptides and Oncology, backed by a much stronger balance sheet.
Why it mattersThe shift toward high-margin science-led APIs and specialized formulations (like Cenobamate) is expected to structurally improve EBITDA margins and drive a significant scale-up in revenue over the next 3 years.
Q1 FY27 Revenue: ₹165.6 CrRevenue Growth (YoY): 11.3%Long-term Revenue Target: ₹1,000 CrDebt-to-Equity Ratio: 0.45Peptide Plant Capacity: 250 kg/annumR&D Spend (% of sales): 2.2%
📅 Short termThe stock may react positively to the margin expansion (Gross Margin up 210 bps) and the clear 10-15% growth guidance for the current fiscal year.
📈 Long termThe company's pivot to complex molecules and oncology, combined with a target to double revenue in 3 years, suggests a potential re-rating if execution timelines for new plants are met.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk in commissioning high-tech peptide and oncology facilities
- Regulatory delays in NCLT approval for the GenRx acquisition
- Geopolitical risks impacting export pricing and oil-linked API costs
Key Highlights
Q1 FY27 revenue increased 11.3% YoY to ₹165.6 Cr, driven by 27% growth in domestic API.
Management set a long-term revenue target of ₹900-1,000 Cr, representing ~138% growth over TTM revenue of ₹420 Cr.
Debt-to-Equity ratio improved to 0.45 from 1.19 in FY24, reflecting significant deleveraging.
New 250 kg/annum peptide manufacturing facility targeted for commissioning by Q4 FY27.
R&D spending as a percentage of sales scaled from 0.4% in 2024 to 2.2% in 2026.
👀 What to Watch
Watch for the timely commissioning of the peptide facility in Q4 FY27 and the NCLT approval for the GenRx facility acquisition, as these are critical for the company's ₹1,000 Cr revenue roadmap.
Q1 FY27 Results: PAT up 15.8% to ₹13.7 Cr; Revenue grows 11.3% YoY to ₹165.6 Cr
Bajaj Healthcare reported a strong start to FY27 with revenue rising 11.3% YoY to ₹165.6 Cr, which represents approximately 39.4% of its TTM revenue in a single quarter. Growth was primarily driven by the domestic API segment, which surged 27.1% YoY, offsetting a 4.1% decline in exports caused by geopolitical issues in West Asia. Profitability improved as EBITDA margins expanded to 17.8% from 17.1% YoY, leading to a PAT of ₹13.7 Cr. A key regulatory milestone was achieved as the company became the first in India to receive SEC recommendation for Cenobamate Tablets.
Confidence: HIGH
What changedThe company delivered double-digit growth in revenue and profit while achieving a major regulatory milestone for a next-generation anti-seizure medication.
Why it mattersThe margin expansion and strong domestic API performance demonstrate operational resilience, while the regulatory progress in regulated markets (EU/UK) and the new R&D center signal a shift toward higher-value products.
Revenue (Q1 FY27): ₹165.6 CrPAT (Q1 FY27): ₹13.7 CrEBITDA Margin: 17.8%Domestic API Growth: 27.1%Q1 Revenue vs TTM Revenue: 39.4%
📅 Short termThe stock may see positive sentiment driven by margin expansion and the regulatory breakthrough for Cenobamate.
📈 Long termStructural growth is supported by the operationalization of the Savli R&D center and increasing approvals in regulated markets, though high debt levels remain a factor to watch.
⚠ Risk flags
- Geopolitical disruptions in West Asia impacting exports
- High debt levels (₹249 Cr) relative to quarterly earnings
- Marginal decline in formulations segment
Key Highlights
Revenue from operations increased 11.3% YoY to ₹165.6 Crore for Q1 FY27.
Domestic API sales grew significantly by 27.1% YoY to ₹92.3 Crore.
Gross margins expanded to 48.3% from 46.2% YoY due to an improved product mix.
Secured SEC recommendation for Cenobamate Tablets, a first for an Indian manufacturer.
Cumulative CEP filings reached 12, with 8 already approved for regulated EU and UK markets.
👀 What to Watch
Monitor the commercialization timeline for Cenobamate Tablets and the recovery of export revenues as geopolitical tensions stabilize. Watch for the impact of the newly operational Savli R&D center on the company's complex product pipeline.
Bajaj Healthcare Q1 PAT Rises 15.7% to ₹13.7 Cr; ₹150 Cr Debt Repaid
Bajaj Healthcare reported a steady Q1 FY27 with revenue growing 11.3% YoY to ₹165.63 Cr. Net profit increased to ₹13.70 Cr from ₹11.83 Cr in the same quarter last year, reflecting improved operational efficiency. A significant highlight is the utilization of ₹150 Cr from the recent ₹204.97 Cr fundraise to repay loans, which should reduce future interest burdens. The company is also awaiting NCLT approval to consolidate its ₹10.85 Cr acquisition of Genrx Pharmaceuticals.
Confidence: HIGH
What changedThe company has transitioned from a period of high debt and exceptional losses (₹33.25 Cr reversal in March 2026) to a cleaner balance sheet with double-digit revenue growth.
Why it mattersThe ₹150 Cr debt repayment significantly strengthens the balance sheet (Net worth is ₹533 Cr), while the growth in continuing operations suggests a recovery from previous drags caused by discontinued units.
Revenue (Q1 FY27): ₹165.63 CrNet Profit (Q1 FY27): ₹13.70 CrDebt Repayment: ₹150 CrDebt Repayment vs Net Worth: ~28.1%Genrx Acquisition Cost: ₹10.85 Cr
📅 Short termThe stock may react positively to the double-digit profit growth and the clear roadmap for the utilization of fundraise proceeds for debt reduction.
📈 Long termStructural improvement is evident through debt reduction and the shift toward higher operational standards by hiring industry veterans, though discontinued operations remain a minor drag.
⚠ Risk flags
- Pending NCLT approval for Genrx acquisition
- Ongoing minor losses from discontinued operations (₹0.19 Cr in Q1)
- Regional instability in Middle East affecting technical know-how income
Key Highlights
Revenue from operations grew 11.3% YoY to ₹165.63 Cr in Q1 FY27.
Net profit (PAT) increased 15.7% YoY to ₹13.70 Cr compared to ₹11.83 Cr in Q1 FY26.
Utilized ₹150 Cr for debt repayment from the total preferential issue proceeds of ₹204.97 Cr.
Finance costs for the quarter stood at ₹6.09 Cr, representing approximately 3.7% of revenue.
Acquisition of Genrx Pharmaceuticals for ₹10.85 Cr is pending NCLT approval for consolidation.
👀 What to Watch
Watch for the final NCLT approval regarding the Genrx acquisition and the impact of reduced debt on interest margins in the coming quarters.
Q1 FY27 Net Profit Up 15.8% YoY to ₹13.70 Cr; Revenue Grows 11.3%
Bajaj Healthcare reported a steady Q1 FY27 with revenue from operations growing 11.3% YoY to ₹165.63 cr. Net profit for the period increased by 15.8% YoY to ₹13.70 cr, reflecting improved operational performance in continuing operations. The company has successfully utilized ₹150 cr from its ₹204.97 cr preferential fundraise for debt repayment, significantly strengthening the balance sheet. Losses from discontinued operations have narrowed to a marginal ₹0.19 cr.
Confidence: HIGH
What changedThe company reported its first-quarter results for FY27, showing growth in both top and bottom lines while confirming the substantial utilization of raised funds for debt reduction.
Why it mattersThe significant debt repayment (₹150 cr) reduces interest costs and financial risk, while the revenue growth suggests the company is successfully scaling its core API and formulation business after a volatile FY26.
Revenue Growth (YoY): 11.3%Net Profit (Q1 FY27): ₹13.70 crDebt Repayment from Funds: ₹150 crUnutilised Fund Balance: ₹11.73 crGenrx Acquisition Cost: ₹10.85 cr
📅 Short termThe results are likely to be viewed positively by the market due to the double-digit profit growth and clear evidence of deleveraging.
📈 Long termThe company is structurally improving by reducing debt and focusing on core operations; the integration of Genrx Pharmaceuticals remains a key long-term growth driver.
⚠ Risk flags
- Pending NCLT approval for Genrx consolidation
- Residual losses from discontinued operations
Key Highlights
Revenue from operations increased 11.3% YoY to ₹165.63 cr from ₹148.84 cr.
Net profit after tax rose 15.8% YoY to ₹13.70 cr compared to ₹11.83 cr in the previous year's quarter.
Utilized ₹150 cr for debt repayment out of the ₹204.97 cr raised through preferential issues.
Capital expenditure (Capex) utilization reached ₹23.31 cr against a planned ₹35 cr.
Loss from discontinued operations reduced to ₹0.19 cr from ₹0.34 cr in Q1 FY26.
👀 What to Watch
Monitor the final NCLT approval for the Genrx Pharmaceuticals acquisition and the impact of the remaining ₹11.69 cr capex on future production capacity.
Bajaj Healthcare First in India to Get SEC Nod for Cenobamate Tablets
Bajaj Healthcare (BHL) has become the first company in India to receive a recommendation from the Subject Expert Committee (SEC) of the CDSCO to manufacture and market Cenobamate Tablets. The recommendation covers six dosage strengths ranging from 12.5mg to 200mg for treating partial-onset seizures in adults. This next-generation antiseizure medication marks a significant entry into the specialty Central Nervous System (CNS) therapy market for the company. The move is expected to enhance BHL's product portfolio and market share in the epilepsy treatment segment.
Key Highlights
First-mover advantage in India for Cenobamate Tablets following SEC recommendation.
Recommended for 6 dosage strengths: 12.5mg, 25mg, 50mg, 100mg, 150mg, and 200mg.
Targets the high-growth Central Nervous System (CNS) specialty segment for adult epilepsy.
Clinical studies indicate significant seizure reduction and high seizure freedom rates for the drug.
👀 What to Watch
This is a positive regulatory milestone that gives BHL a competitive edge in the CNS segment; investors should monitor the timeline for final marketing approval and commercial launch.
Bajaj Healthcare Closes Trading Window for Business Unit Sale and Q1 FY27 Results
Bajaj Healthcare Limited has announced a trading window closure for designated persons starting June 23, 2026, in relation to the sale of an operational business unit. A second closure will commence on July 1, 2026, for the declaration of un-audited financial results for the quarter ending June 30, 2026. Both windows will remain closed until 48 hours after the respective events (signing of definitive agreements and results declaration). This is a mandatory compliance step under SEBI Insider Trading Regulations.
Key Highlights
Trading window closed from June 23, 2026, due to the sale of an operational business unit.
Closure for the business sale remains until 48 hours after the execution of definitive agreements.
Quarterly results trading window closure begins July 1, 2026, for the period ending June 30, 2026.
Restrictions apply to all Designated Persons and their immediate relatives per SEBI PIT Regulations.
The company previously disclosed the business unit sale on June 23, 2026, under Regulation 30.
👀 What to Watch
Investors should monitor for the formal execution of the business unit sale agreements as this could impact the company's asset base and valuation. No immediate action is required as this is a standard regulatory filing.
Bajaj Healthcare FY26 Revenue Up 12.6% to ₹611 Cr; Net Profit Drops 60% on Exceptional Loss
Bajaj Healthcare reported a 12.6% YoY growth in annual revenue to ₹61,103 Lakhs for FY26. However, the company faced a significant net loss of ₹2,285 Lakhs in Q4 FY26, primarily due to a one-time exceptional item of ₹3,324 Lakhs related to a technical know-how income reversal from a Middle East contract. Annual net profit consequently declined by 60% to ₹1,576 Lakhs. Despite the profit hit, the board recommended a final dividend of ₹1.50 per share and successfully utilized ₹15,000 Lakhs from warrant conversions for debt repayment.
Key Highlights
Annual Revenue from continuing operations grew 12.6% YoY to ₹61,103.14 Lakhs.
Q4 FY26 reported a net loss of ₹2,285.06 Lakhs vs a profit of ₹1,117.78 Lakhs in the previous year's quarter.
Exceptional loss of ₹3,324.66 Lakhs recognized in Q4 due to reversal of income from a technical know-how arrangement.
Board recommended a final dividend of 30% (₹1.50 per equity share) for FY 2025-26.
Company utilized ₹15,000 Lakhs from preferential issue proceeds for loan repayment, significantly reducing debt.
👀 What to Watch
Investors should monitor the company's ability to stabilize margins following the one-time income reversal and the progress of the Genrx Pharmaceuticals acquisition. While the debt reduction is a positive structural change, the volatility in contract-based income suggests a need for caution.
Bajaj Healthcare FY26 PAT Rises 27% to ₹545.6 Mn; API Exports Surge 51.6%
Bajaj Healthcare reported a 12.6% YoY revenue growth for FY26, reaching ₹6,110.3 Mn, driven primarily by a robust 51.6% surge in API exports. While Q4 revenue was flat due to domestic API price erosion, PAT from continuing operations grew 19.3% in Q4 and 27.1% for the full year. The company strengthened its balance sheet by raising ₹527 Mn through warrant conversion and expanded its pipeline with 41 new DMF filings in Q4. However, a one-time reversal of income from a Middle East contract due to regional instability impacted the final reported profit.
Key Highlights
FY26 Revenue grew 12.6% to ₹6,110.3 Mn, with API exports jumping 51.6% to ₹1,881.4 Mn.
PAT from continuing operations (before exceptional items) increased 27.1% YoY to ₹545.6 Mn in FY26.
Company filed 41 DMFs in Q4 FY26, bringing the cumulative total to 110 to target regulated markets.
Raised ₹527 Mn through the conversion of 2,079,409 warrants into equity shares to support growth.
Cenobamate (anti-epileptic) is on track for a Q2 FY27 launch following Phase III trials.
👀 What to Watch
Investors should monitor the successful launch of Cenobamate in Q2 FY27 and the scaling of the CDMO segment as key growth drivers. The strong export momentum and regulatory filings suggest a positive shift towards higher-margin regulated markets.
Bajaj Healthcare FY26 Revenue Grows 12.6% to ₹611 Cr; Net Profit Falls 60% on Exceptional Item
Bajaj Healthcare reported a 12.6% year-on-year growth in annual revenue to ₹61,103.14 Lakhs for FY26. However, Net Profit for the year declined sharply to ₹1,576.61 Lakhs from ₹3,949.55 Lakhs in FY25, primarily due to a one-time exceptional charge of ₹3,324.66 Lakhs involving the reversal of technical know-how income. The company reported a net loss of ₹2,285.06 Lakhs in Q4 FY26. Despite the profit decline, the board has recommended a final dividend of ₹1.50 per share (30% of face value).
Key Highlights
Annual Revenue from operations increased to ₹61,103.14 Lakhs in FY26 vs ₹54,260.24 Lakhs in FY25.
Net Profit for FY26 dropped 60% YoY to ₹1,576.61 Lakhs, impacted by a ₹3,324.66 Lakhs exceptional income reversal due to Middle East instability.
Q4 FY26 recorded a net loss of ₹2,285.06 Lakhs compared to a profit of ₹1,117.78 Lakhs in the same quarter last year.
Recommended a final dividend of ₹1.50 per equity share (30% of Face Value of ₹5).
Raised ₹17,300.18 Lakhs through preferential issues and warrant conversions, with ₹15,000 Lakhs utilized for loan repayment.
👀 What to Watch
Investors should treat the Q4 loss as largely driven by a one-time accounting reversal, but must monitor if geopolitical issues continue to hinder technical know-how exports. The significant reduction in debt through warrant conversion is a positive long-term development for the balance sheet.
Bajaj Healthcare Reports FY26 Revenue Growth of 12.6%; Recommends Rs 1.50 Dividend
Bajaj Healthcare reported a 12.6% YoY increase in FY26 revenue to Rs. 611.03 crore, though net profit fell significantly to Rs. 15.77 crore from Rs. 39.50 crore in FY25. The Q4 performance was severely impacted by a one-time exceptional loss of Rs. 33.25 crore due to the reversal of technical know-how income linked to Middle East instability. Despite a Q4 net loss of Rs. 22.85 crore, the board recommended a final dividend of Rs. 1.50 per share. The company also strengthened its capital base by raising Rs. 52.71 crore through warrant conversions.
Key Highlights
FY26 Revenue from operations increased to Rs. 61,103.14 lakhs from Rs. 54,260.24 lakhs in FY25.
Reported a significant exceptional item of Rs. 3,324.66 lakhs in Q4 FY26 due to income reversal.
Total Net Profit for FY26 dropped to Rs. 1,576.61 lakhs compared to Rs. 3,949.55 lakhs in the previous year.
Recommended a final dividend of Rs. 1.50 per equity share (30% of face value of Rs. 5).
Raised Rs. 5,271.30 lakhs through the conversion of 20,79,409 warrants into equity shares for debt repayment and CAPEX.
👀 What to Watch
Investors should exercise caution as the sharp decline in profitability and the large income reversal indicate high sensitivity to geopolitical risks. Monitor the successful integration of the Genrx acquisition and the impact of debt repayment on future margins.
Bajaj Healthcare FY26 Revenue Up 12.6%; Q4 Hit by ₹33.2 Cr Exceptional Loss
Bajaj Healthcare reported a 12.6% YoY growth in annual revenue to ₹611.03 crore for FY26. However, annual net profit declined sharply to ₹15.77 crore from ₹39.50 crore in the previous year, primarily due to a significant exceptional item in Q4. The company reversed ₹33.25 crore of income related to a technical know-how transfer due to regional instability in the Middle East. Despite the quarterly loss of ₹22.85 crore, the board has recommended a final dividend of ₹1.50 per share.
Key Highlights
Annual revenue from operations increased to ₹611.03 crore in FY26 from ₹542.60 crore in FY25.
Q4 FY26 recorded a net loss of ₹22.85 crore compared to a profit of ₹11.18 crore in Q4 FY25.
Exceptional loss of ₹33.25 crore due to reversal of technical know-how income from a Middle East customer.
Company successfully raised ₹204.97 crore through warrants, utilizing ₹150 crore for debt repayment.
Board recommended a final dividend of 30% (₹1.50 per equity share of face value ₹5).
👀 What to Watch
Investors should be cautious regarding the volatility in earnings caused by geopolitical issues, though the substantial debt repayment of ₹150 crore strengthens the balance sheet. Monitor the NCLT approval for the Genrx Pharmaceuticals acquisition as a potential future growth driver.
Bajaj Healthcare Receives Listing Approval for 20.79 Lakh Equity Shares
Bajaj Healthcare Limited has received in-principle approval from both NSE and BSE for the listing of 20,79,409 equity shares of face value ₹5 each. These shares were allotted following the conversion of warrants previously issued on a preferential basis. The listing will proceed once the company receives confirmation of credit from the depositories (NSDL and CDSL). This move completes a stage of the company's capital raising process, increasing the total outstanding equity shares.
Key Highlights
Listing approval granted for 20,79,409 equity shares of ₹5 face value each
Shares issued pursuant to conversion of warrants on a preferential basis
In-principle approval received from both BSE Limited and National Stock Exchange of India
New shares carry distinctive numbers from 31583253 to 33662661
Trading to commence post confirmation of credit from NSDL/CDSL
👀 What to Watch
Investors should account for the slight dilution in Earnings Per Share (EPS) resulting from the increased share capital. No immediate action is required as this is a procedural step following a prior preferential allotment.
Bajaj Healthcare Allots 20.79 Lakh Shares on Warrant Conversion; Raises ₹52.71 Cr
Bajaj Healthcare Limited has successfully completed the allotment of 20,79,409 equity shares following the conversion of warrants issued in September 2024. The conversion was executed at a price of ₹338 per share, resulting in a total capital infusion of approximately ₹70.28 crore, with ₹52.71 crore received as the final 75% payment. The allotment includes participation from both promoters and non-promoter public investors, indicating strong confidence in the company's prospects. Consequently, the company's paid-up equity capital has increased to ₹16.83 crore, and no warrants remain outstanding.
Key Highlights
Allotment of 20,79,409 equity shares at an issue price of ₹338 per share (including ₹333 premium).
Total funds raised through this warrant exercise aggregate to ₹70.28 crore.
Company received ₹52.71 crore as the final 75% balance consideration from 8 allottees.
Promoter Sajankumar Rameshwarlal Bajaj's post-issue holding stands at 36.62% (1,23,25,774 shares).
Total paid-up share capital increased from 3,15,83,252 to 3,36,62,661 equity shares of ₹5 each.
👀 What to Watch
The successful conversion of warrants and the resulting capital infusion strengthen the company's balance sheet and reflect promoter commitment. Investors should monitor the company's upcoming quarterly results to see how this additional capital is deployed for growth.
Bajaj Healthcare Shareholders Approve Re-appointment of CMD and 6 Other Directors
Bajaj Healthcare Limited has successfully passed seven special resolutions via postal ballot as of February 19, 2026. Key approvals include the re-appointment of Mr. Sajankumar Rameshwarlal Bajaj as Chairman & Managing Director and Mr. Anil Champalal Jain as Managing Director. The company also appointed three new Non-Executive Independent Directors to its board. While all resolutions passed with the requisite majority, Resolution 7 faced significant dissent from public institutional voters.
Key Highlights
Re-appointment of Sajankumar Rameshwarlal Bajaj as CMD passed with 99.99% of total votes in favor.
Three new Independent Directors (Mr. Vaghela, Mrs. Amin, and Mr. Bhavsar) were officially inducted into the board.
Total of 19.3 million votes were polled, representing 61.13% of the total outstanding shares.
Resolution 7 regarding the re-appointment of Mr. Pakshal Anil Jain saw 99.99% of voting public institutions (599,840 votes) voting against.
All 7 resolutions were special resolutions and passed with the required majority as per SEBI regulations.
👀 What to Watch
The approval ensures management continuity, which is generally stable for the stock. However, investors should monitor the reasons behind the high institutional dissent on Resolution 7 to evaluate any underlying corporate governance concerns.
Bajaj Healthcare Q3 PAT Rises 34% to ₹15.67 Cr; Key Management Re-appointed
Bajaj Healthcare reported a strong 31.3% YoY growth in revenue from operations, reaching ₹161.22 crore for Q3 FY26. Net profit for the quarter surged by 33.7% YoY to ₹15.67 crore, aided by improved performance in continuing operations and significantly reduced losses from discontinued units. The company also announced the re-appointment of its top leadership, including the Chairman and Managing Directors, for another three-year term starting April 2026. Nine-month performance remains robust with total profit increasing to ₹38.62 crore compared to ₹28.32 crore in the previous year.
Key Highlights
Revenue from operations grew 31.3% YoY to ₹16,122.27 lakhs in Q3 FY26.
Net profit for the period increased 33.7% YoY to ₹1,567.38 lakhs.
9M FY26 total income reached ₹46,215.16 lakhs compared to ₹39,396.27 lakhs in 9M FY25.
Losses from discontinued operations narrowed significantly to ₹42.71 lakhs from ₹324.44 lakhs YoY.
Board approved the re-appointment of the core promoter management team for a 3-year term starting April 2026.
👀 What to Watch
Investors should view the strong top-line and bottom-line growth as a positive sign of operational efficiency and scale. The continuity in leadership provides stability, though investors should monitor the final disposal of discontinued assets.
Bajaj Healthcare Seeks Shareholder Approval for 7 Director Appointments and Re-appointments
Bajaj Healthcare has issued a postal ballot notice to seek shareholder approval for the appointment of three Independent Directors and the re-appointment of four key executive leaders. The executive re-appointments, including the Chairman & Managing Director and Managing Director, are for three-year terms starting April 1, 2026. The three new Independent Directors are proposed for five-year terms to enhance board oversight and governance. Shareholders can cast their votes electronically from January 20 to February 19, 2026.
Key Highlights
Re-appointment of Sajankumar Rameshwarlal Bajaj as CMD for a 3-year term starting April 1, 2026
Proposed appointment of 3 new Independent Directors for 5-year terms to strengthen board governance
Re-appointment of Anil Champalal Jain as MD and two other Whole-Time Directors for 3-year terms
E-voting period scheduled from January 20, 2026, to February 19, 2026
Cut-off date for eligibility to vote is January 16, 2026
👀 What to Watch
Shareholders should review the profiles of the proposed directors and participate in the e-voting process to ensure leadership stability. Leadership continuity is generally a positive sign for the execution of the company's long-term strategy.
Bajaj Healthcare Q3 FY26: Revenue Up 31%, API Exports Surge 110% YoY
Bajaj Healthcare reported a strong Q3 FY26 with revenue growing 31.3% YoY to Rs. 1,612.2 Mn, primarily driven by a massive 109.8% surge in API exports. EBITDA margins improved slightly to 19.8%, leading to a 33.7% YoY increase in net profit to Rs. 156.7 Mn. The company achieved a significant regulatory milestone as the first Indian firm to receive CDSCO approval for Phase III trials of Suvorexant. For the nine-month period, PAT grew by 36.4%, reflecting sustained momentum in regulated markets and specialty drug development.
Key Highlights
Revenue from operations grew 31.3% YoY to Rs. 1,612.2 Mn in Q3 FY26.
API Export revenue more than doubled, growing 109.8% YoY to Rs. 486.8 Mn.
EBITDA increased by 34.6% YoY to Rs. 323.3 Mn with margins expanding to 19.8%.
Profit for the period (PAT) rose 33.7% YoY to Rs. 156.7 Mn.
Filed 9 DMFs during the quarter, bringing the cumulative total to 69 filings.
👀 What to Watch
The company shows strong momentum in high-margin API exports and a successful transition towards regulated markets. Investors should monitor the progress of Phase III clinical trials for Suvorexant and Cenobamate as these represent high-value specialty opportunities.
